Insulin aspart, recombinant Subcutaneous and Meropenem Intravenous
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Meropenem Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: meropenem
Brand name: Merrem, Merrem Novaplus
Synonyms: Meropenem
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Merrem
- Insulin aspart, recombinant Subcutaneous-Merrem IV
- Insulin aspart, recombinant Subcutaneous-Merthiolate
- Insulin aspart, recombinant Subcutaneous-Meruvax II
- Insulin aspart, recombinant Subcutaneous-Mesalamine
- Insulin aspart, recombinant Subcutaneous-Mesalamine Controlled-Release Capsules
- Meropenem Intravenous-Insulin degludec
- Meropenem Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Meropenem Intravenous-Insulin Degludec (U-100) Vials
- Meropenem Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Meropenem Intravenous-Insulin degludec and liraglutide
- Meropenem Intravenous-Insulin degludec and liraglutide Subcutaneous